Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.67 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.67 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.67 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30626035 | 1.00 | KMT2A (0.67) | KMT2AMEN1NPC1RAB9ASENP8 | |
| SCHEMBL196710 | 0.80 | TDP1 (0.52) | KMT2AMEN1NPC1RAB9ASENP8 | |
| SCHEMBL30626039 | 0.80 | CA1 (0.47) | KMT2AMEN1NPC1RAB9ASENP8 | |
| SCHEMBL30217935 | 0.80 | TDP1 (0.52) | KMT2AMEN1NPC1RAB9ASENP8 | |
| SCHEMBL17355690 | 0.78 | KMT2A (0.52) | KMT2AMEN1NPC1RAB9ASENP8 | |
| SCHEMBL10652711 | 0.78 | MEN1 (0.52) | KMT2AMEN1NPC1RAB9ASENP8 | |
| SCHEMBL7180736 | 0.78 | CA1 (0.48) | KMT2AMEN1NPC1RAB9ASENP8 | |
| SCHEMBL1176512 | 0.76 | CA1 (0.47) | KMT2AMEN1NPC1RAB9ASENP8 | |
| SCHEMBL6580142 | 0.76 | CA1 (0.47) | KMT2AMEN1NPC1RAB9ASENP8 | |
| SCHEMBL10849987 | 0.76 | CA1 (0.52) | KMT2AMEN1NPC1RAB9ASENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3306732-B1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR BATTERIES AND LITHIUM SECONDARY BATTERY | MITSUI CHEMICALS INC (JP) | 2025-06-25 | — | — | EP | disclosed |
| CN-107534185-B | Nonaqueous electrolyte for battery and lithium secondary battery | 三井化学株式会社 | 2021-10-08 | — | — | CN | disclosed |
| EP-3343687-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR BATTERIES AND LITHIUM SECONDARY BATTERY COMPRISING THE SAME | MITSUI CHEMICALS INC (JP) | 2021-02-24 | — | — | EP | disclosed |
| US-20180241084-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR BATTERY AND LITHIUM SECONDARY BATTERY | MITSUI CHEMICALS, INC. (JP) | 2018-08-23 | — | — | US | disclosed |
| EP-3343687-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR BATTERIES AND LITHIUM SECONDARY BATTERY | Mitsui Chemicals, Inc. (JP) | 2018-07-04 | — | — | EP | disclosed |
| US-20180138551-A1 | NON-AQUEOUS ELECTROLYTE SOLUTION FOR BATTERY AND LITHIUM SECONDARY BATTERY | MITSUI CHEMICALS, INC. (JP) | 2018-05-17 | — | — | US | disclosed |
| EP-3306732-A1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR BATTERIES AND LITHIUM SECONDARY BATTERY | Mitsui Chemicals, Inc. (JP) | 2018-04-11 | — | — | EP | disclosed |
| US-20170346127-A1 | LITHIUM SECONDARY BATTERY | MITSUI CHEMICALS, INC. (JP) | 2017-11-30 | — | — | US | disclosed |
| EP-3211706-A1 | LITHIUM SECONDARY BATTERY | Mitsui Chemicals, Inc. (JP) | 2017-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170346127-A1 | LITHIUM SECONDARY BATTERY | SLC9B2, SCN11A, NUCB2 | KMT2A 1527/4885MEN1 1809/4885NPC1 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.